Tim Meyer

Tim Meyer, PhD, FRCP is Professor of Oncology at University College London Cancer Institute and a Consultant Medical Oncologist at the Royal Free Hospital, where he leads one of the UK's most active liver cancer clinical research programs. He has been a central figure in the global clinical trial enterprise for HCC and biliary tract cancers, serving as national PI or steering committee member for many pivotal phase II/III studies. Dr. Meyer's scientific contributions span combination immunotherapy strategies for HCC, the rational integration of locoregional therapies (TACE) with systemic agents, and the development of circulating tumor DNA (ctDNA) as a biomarker for early detection, treatment monitoring, and prediction of recurrence in hepatobiliary cancers. He has investigated the immune modulatory effects of TACE and ablation in HCC, providing the biological rationale for combining locoregional approaches with checkpoint inhibitors—a strategy now being evaluated in the EMERALD-1 and LEAP-012 trials. His group has also contributed to understanding the molecular basis of primary and acquired resistance to antiangiogenic therapy in HCC, including FGF19 amplification and mTOR pathway activation.